Roth Capital Weighs in on Clene’s Q1 Earnings (NASDAQ:CLNN)

Clene Inc. (NASDAQ:CLNN) – Equities research analysts at Roth Capital decreased their Q1 2025 EPS estimates for Clene in a research report issued on Monday, March 24th. Roth Capital analyst J. Aschoff now expects that the company will earn ($1.09) per share for the quarter, down from their prior estimate of ($0.86). The consensus estimate for Clene’s current full-year earnings is ($5.19) per share. Roth Capital also issued estimates for Clene’s Q2 2025 earnings at ($0.92) EPS, Q3 2025 earnings at ($0.92) EPS, Q4 2025 earnings at ($0.80) EPS, FY2025 earnings at ($3.68) EPS and FY2026 earnings at ($2.85) EPS.

Clene (NASDAQ:CLNN) last posted its quarterly earnings data on Monday, March 24th. The company reported ($1.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.21) by ($0.46). The firm had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.13 million. Clene had a negative return on equity of 1,106.30% and a negative net margin of 8,556.77%.

A number of other analysts have also commented on the company. HC Wainwright reiterated a “buy” rating and issued a $31.00 price objective on shares of Clene in a research report on Monday. D. Boral Capital reiterated a “buy” rating and set a $23.00 price target on shares of Clene in a research report on Monday. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $55.25.

Clene Stock Down 10.2 %

CLNN stock opened at $3.18 on Thursday. Clene has a twelve month low of $3.09 and a twelve month high of $9.20. The company has a market cap of $26.48 million, a P/E ratio of -0.60 and a beta of 0.27. The business has a fifty day moving average of $4.46 and a 200-day moving average of $4.87.

Institutional Investors Weigh In On Clene

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CLNN. SBI Securities Co. Ltd. bought a new position in Clene during the fourth quarter worth about $69,000. Fullcircle Wealth LLC acquired a new stake in shares of Clene in the 4th quarter valued at approximately $69,000. Renaissance Technologies LLC acquired a new stake in shares of Clene in the 4th quarter valued at approximately $96,000. Parsons Capital Management Inc. RI bought a new position in Clene during the 4th quarter worth approximately $194,000. Finally, Geode Capital Management LLC grew its holdings in Clene by 52.9% during the fourth quarter. Geode Capital Management LLC now owns 65,112 shares of the company’s stock valued at $346,000 after purchasing an additional 22,539 shares during the period. Institutional investors own 23.28% of the company’s stock.

About Clene

Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.